Jill O'Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs
Jill O’Donnell-Tormey, Ph.D., is chief executive officer and director of scientific affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 and the only nonprofit dedicated exclusively to the support and coordination of laboratory and clinical research efforts leading to the immunological treatment, control, and prevention of cancer. She joined the organization in 1987 as director of scientific affairs, and has been chief executive since 1993.
Dr. O’Donnell-Tormey is a member of the Management Team of the Cancer Vaccine Collaborative (CVC), a joint program between CRI and the Ludwig Institute for Cancer Research comprising a global network of academic clinical trial sites with immunological monitoring expertise conducting centrally coordinated, parallel, early-stage clinical trials of therapeutic cancer vaccines. She is also a member of the Executive Committee of the CRI Cancer Immunotherapy Consortium (CIC), an association of 100 biotechnology and pharmaceutical companies and academic institutions dedicated to making cancer immunotherapy part of the standard of care in cancer patient treatment.
She serves on the boards of Zero: The Project to End Prostate Cancer (formerly the National Prostate Cancer Coalition); CT Atlantic AG, a Swiss biotechnology company focusing on the research and development of novel, human-derived antibodies for the treatment of cancer; and the Staten Island Foundation. In 1998, she was named one of Irish America magazine’s “Top 100” Irish Americans, and in 2002 she received the Fairleigh Dickinson University Pinnacle Award, the highest honor bestowed on its alumni.
She holds a Bachelor of Science degree in chemistry, summa cum laude, from Fairleigh Dickinson University and a doctor of philosophy in cell biology from The State University of New York’s Downstate Medical Center.